Disease · MONDO_0005102
undifferentiated (embryonal) sarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. undifferentiated (embryonal) sarcoma. Diseases, record MONDO_0005102. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005102
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- UES, embryonal sarcoma, embryonal sarcoma (undifferentiated sarcoma), embryonal sarcoma, undifferentiated, sarcoma, undifferentiated, malignant, undifferentiated sarcoma
- Open Targets
Drugs20
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| DACTINOMYCIN | CHEMBL1554 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IFOSFAMIDE | CHEMBL1024 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPIRUBICIN HYDROCHLORIDE | CHEMBL1200981 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IDARUBICIN | CHEMBL1117 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SARGRAMOSTIM | CHEMBL1201670 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 20
See all 20 drugsTargets24
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 24
See all 24 targetsTrials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02406781 | Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial | Phase 2 | 129 | 2025-12-10 | Sarcoma | CYCLOPHOSPHAMIDE, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | Phase 2 | 72 | 2016-12-28 | Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7 | ALISERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT00002995 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma | Phase 3 | 483 | Sarcoma | CYCLOPHOSPHAMIDE, DACTINOMYCIN, FILGRASTIM, SARGRAMOSTIM, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00002898 | Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma | Phase 3 | 400 | Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma | CARBOPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, EPIRUBICIN HYDROCHLORIDE, ETOPOSIDE, IFOSFAMIDE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00876031 | Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma | Phase 3 | 195 | Soft Tissue Sarcoma | ETOPOSIDE, IDARUBICIN, TROFOSFAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00025363 | Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma | Phase 2 | 150 | Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, IFOSFAMIDE, IRINOTECAN, TIRAPAZAMINE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | Phase 1 | 18 | Metastatic Soft-tissue Sarcoma | IPILIMUMAB, NIVOLUMAB, ZANZALINTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03111069 | Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children | Phase 1 | 0 | Malignant Neoplasms of Mesothelial and Soft Tissue, Rhabdomyosarcoma, Pelvic, Rhabdomyosarcoma, Abdominal | DOXORUBICIN | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005102
GET https://conductscience.org/api/diseases/v1/MONDO_0005102/targets?page=2